ICICI Prudential Pharma Healthcare & Diagnostics Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹5,000

ICICI Prudential Pharma Healthcare & Diagnostics Growth Direct Plan

NAV
₹32.2000
-0.77%
(18 Apr)
AUM
3,772 Cr
TER
1.04%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+98.7%
+96.7%
+80.4%
+65.1%
+57.8%
3Y
+46.5%
+43.0%
+42.1%
+41.7%
+18.8%
5Y
NA
+24.4%
+36.6%
+27.1%
+25.3%
ALL
+34.1%
+12.7%
+20.7%
+18.0%
+22.5%
VOL
21.8%
19.9%
20.2%
18.1%
15.4%
TER
0.5%
1.0%
0.7%
1.0%
1.0%
AUM
₹3,404 Cr
₹1,876 Cr
₹2,498 Cr
₹5,186 Cr
₹3,772 Cr
INFO
1.56
0.64
1.02
0.99
1.46
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
ICICI Pru Pharma Healthcare & Diagnostics (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 29th Feb
Top holdings
Sun Pharmaceuticals Industries Ltd
17.0%
Dr Reddy's Laboratories Ltd
8.1%
Lupin Ltd
6.6%
Cipla Ltd
6.3%
Aurobindo Pharma Ltd
6.0%
Apollo Hospitals Enterprise Ltd
5.9%
Divi's Laboratories Ltd
5.3%
Zydus Lifesciences Ltd
3.1%
Mankind Pharma Ltd
2.9%
Alkem Laboratories Ltd
2.6%
Top industry exposure
Healthcare
90.6%
Financial Services
2.8%
Basic Materials
1.7%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
70%
Lock-in period
-
Exit load
• 1% for redemption within 15 days
Fund objective
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Fund manager(s)
Dharmesh Kakkad
Sharmila D’mello

FAQs